 Multidrug Resistance-Associated Proteins
"Multidrug Resistance-Associated Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sequence-related subfamily of ATP-BINDING CASSETTE TRANSPORTERS that actively transport organic substrates. Although considered organic anion transporters, a subset of proteins in this family have also been shown to convey drug resistance to neutral organic drugs. Their cellular function may have clinical significance for CHEMOTHERAPY in that they transport a variety of ANTINEOPLASTIC AGENTS. Overexpression of proteins in this class by NEOPLASMS is considered a possible mechanism in the development of multidrug resistance (DRUG RESISTANCE, MULTIPLE). Although similar in function to P-GLYCOPROTEINS, the proteins in this class share little sequence homology to the ATP-BINDING CASSETTE, SUB-FAMILY B, MEMBER 1 family of proteins.
| Descriptor ID |
D027425
|
| MeSH Number(s) |
D12.776.157.530.100.304 D12.776.157.530.450.074.500.500.500 D12.776.543.585.100.304 D12.776.543.585.450.074.500.500.500
|
| Concept/Terms |
Multidrug Resistance-Associated Proteins- Multidrug Resistance-Associated Proteins
- Multidrug Resistance Associated Proteins
- Multispecific Organic Anion Transporter
- Multispecific Organic Anion Transport Proteins
- ATP-Binding Cassette, Sub-Family C Proteins
- ATP Binding Cassette, Sub Family C Proteins
- MOAT Protein
- Multidrug Resistance-Associated Protein
- Multidrug Resistance Associated Protein
- Resistance-Associated Protein, Multidrug
|
Below are MeSH descriptors whose meaning is more general than "Multidrug Resistance-Associated Proteins".
Below are MeSH descriptors whose meaning is more specific than "Multidrug Resistance-Associated Proteins".
This graph shows the total number of publications written about "Multidrug Resistance-Associated Proteins" by people in this website by year, and whether "Multidrug Resistance-Associated Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2004 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2012 | 0 | 2 | 2 | | 2013 | 1 | 0 | 1 | | 2017 | 0 | 2 | 2 | | 2018 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Multidrug Resistance-Associated Proteins" by people in Profiles.
-
El Kasmi KC, Ghosh S, Anderson AL, Devereaux MW, Balasubramaniyan N, D'Alessandro A, Orlicky DJ, Suchy FJ, Shearn CT, Sokol RJ. Pharmacologic activation of hepatic farnesoid X receptor prevents parenteral nutrition-associated cholestasis in mice. Hepatology. 2022 02; 75(2):252-265.
-
El Kasmi KC, Vue PM, Anderson AL, Devereaux MW, Ghosh S, Balasubramaniyan N, Fillon SA, Dahrenmoeller C, Allawzi A, Woods C, McKenna S, Wright CJ, Johnson L, D'Alessandro A, Reisz JA, Nozik-Grayck E, Suchy FJ, Sokol RJ. Macrophage-derived IL-1?/NF-?B signaling mediates parenteral nutrition-associated cholestasis. Nat Commun. 2018 04 11; 9(1):1393.
-
Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant C, Bowles DW, George B, Wen X, Aleksunes LM, Joy MS. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin. Int J Mol Sci. 2017 Jun 22; 18(7).
-
Charkoftaki G, Chen Y, Han M, Sandoval M, Yu X, Zhao H, Orlicky DJ, Thompson DC, Vasiliou V. Transcriptomic analysis and plasma metabolomics in Aldh16a1-null mice reveals a potential role of ALDH16A1 in renal function. Chem Biol Interact. 2017 Oct 01; 276:15-22.
-
Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet. 2013 Sep; 52(9):751-62.
-
Martin LJ, Lau E, Singh H, Vergnes L, Tarling EJ, Mehrabian M, Mungrue I, Xiao S, Shih D, Castellani L, Ping P, Reue K, Stefani E, Drake TA, Bostrom K, Lusis AJ. Response to Pomozi et al's research commentary. Circ Res. 2013 May 24; 112(11):e152-3.
-
Pattabiraman PP, Pecen PE, Rao PV. MRP4-mediated regulation of intracellular cAMP and cGMP levels in trabecular meshwork cells and homeostasis of intraocular pressure. Invest Ophthalmol Vis Sci. 2013 Mar 05; 54(3):1636-49.
-
Fukuda T, Goebel J, Cox S, Maseck D, Zhang K, Sherbotie JR, Ellis EN, James LP, Ward RM, Vinks AA. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients. Ther Drug Monit. 2012 Dec; 34(6):671-9.
-
Martin LJ, Lau E, Singh H, Vergnes L, Tarling EJ, Mehrabian M, Mungrue I, Xiao S, Shih D, Castellani L, Ping P, Reue K, Stefani E, Drake TA, Bostrom K, Lusis AJ. ABCC6 localizes to the mitochondria-associated membrane. Circ Res. 2012 Aug 17; 111(5):516-20.
-
Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res. 2012 Apr 01; 18(7):2099-107.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|